New York, NY -- (SBWIRE) -- 03/17/2021 -- The Global Non-Small Cell Lung Cancer Market is forecast to reach USD 10.53 Billion by 2026, according to a new report by Reports and Data. Non-small cell lung cancer accounts for approximately 85% of all lung cancers.

The rise in the number of people suffering from non-small cell lung cancer is one of the major factors driving the global non-small cell lung cancer drugs market growth. The risk factors such as air pollution, cigarette smoking, passive smoking, and occupational exposure are increasing the incidence of the disease globally. One of the major drivers of the non-small cell lung cancer is the strong drug pipeline and recent drug approvals. The innovation of new drugs and their approvals for the treatment of the disease is anticipated to fuel the growth of the market.

Top Players Covered in the Report Include:
Tarceva, Avastin, Gemzar, Alimta, Taxotere, AstraZeneca, Roche, Merck KGa, Nlyte, and Panduit Corp. among others.

One of the challenges of the non-small cell lung cancer market is the high cost of treatment. The disease can be treated by chemotherapy, surgery, targeted therapies, radiation therapy, and immunotherapy, which is quite expensive. Thus, the high cost of the treatment will hamper the growth of the market.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1475

Further key findings from the report suggest
Smoking causes ~90% of lung cancer cases. Constant exposure to the high level of air pollution and drinking water with a high level of arsenic increases the odds of lung cancer.

The most common type of non-small cell lung cancer are adenocarcinomas, squamous cell carcinoma, and large cell carcinomas.

Squamous cell carcinoma is the second most common form of lung cancer. This type of lung cancer is found in the middle of the lungs. It is forecasted to hold a market share of 37% in the year 2026.

Adenocarcinoma held a market share of 48% in the year 2018. The disease tends to develop in smaller airways such as bronchioles, breasts, prostate, pancreas, and colon.

Adenocarcinoma accounts for approximately more than 40% of lung cancer and is found mostly in women and grows more slowly than any other cancers.

Surgery is expected to grow at a CAGR of 6.8% during the forecast period. It is an option to be performed at an early stage and is the best chance to cure the disease.

Types of lung cancer surgeries include pneumonectomy, lobectomy, segmentectomy or wedge resection, and sleeve resection.

Chemotherapy is a treatment with anti-cancer drugs that are injected into a vein or taken by mouth. The treatment is useful for treating cancer anywhere in the body.

Doctors recommend chemotherapy in combination with definitive radiation treatments for patients with stage III lung cancer that cannot be removed surgically. In stage IV, radiation is used only for palliation of the symptoms.

Angiogenesis inhibitor is a substance that inhibits the growth off new blood vessels. It held a market share of 16% in the year 2018.

The market in Asia Pacific is anticipated to be the leading contributor in the non-small cell lung cancer market. Rising awareness regarding cancer and initiatives taken by the governments in the region to encourage the treatment of lung cancer through medicines in public healthcare centers and subsidized treatment will fuel the market growth.

For the purpose of this report, Reports and Data have segmented the global Non-Small Cell Lung Cancer Market on the basis of Histology, Treatment, Drug Class, and Region:

Histology Outlook (Revenue, USD Billion; 2016-2026)
Squamous Cell Carcinoma
Large Cell Carcinoma
Adenocarcinoma

Treatment Outlook (Revenue, USD Billion; 2016-2026)
Surgery
Radiation
Chemotherapy
Targeted Therapy Drugs

Drug Class Outlook (Revenue, USD Billion; 2016-2026)
Angiogenesis Inhibitor
Epidermal Growth Factor Receptor Blocker
Kinase Inhibitor
Microtubule Stabilizer
Folate Antimetabolites
PD-1/ PD-L1 Inhibitor

Regional Outlook (Revenue, USD Billion; 2016-2026)
North America
U.S.
Europe
UK
France
Asia Pacific
China
India
Japan
MEA
Latin America
Brazil

Key Points of the Non-Small Cell Lung Cancer report:
Comprehensive analysis of the market including risks and opportunities
Details of business strategies and plans undertaken by key market players
Analysis of current and future trends that will affect the growth of the market in the forecast timeline
In-depth analysis of drivers and constraints for better understanding of the market
Strategic recommendations to the new entrants as well as established players to formulate informed business decisions
Comprehensive overview of the competitive landscape
In-depth analysis of the key regions of the market along with analysis of market share, size, revenue, production and consumption patterns, supply and demand dynamics, among others
Analysis of segments exhibiting promising growth over the forecast period

Table Of Contents
Chapter 1. Market Synopsis
1.1. Market Definition
1.2. Research Scope & Premise
1.3. Methodology
1.4. Market Estimation Technique

Chapter 2. Executive Summary
2.1. Summary Snapshot, 2018-2026

Chapter 3. Indicative Metrics

Chapter 4. Non-Small Cell Lung Cancer Market Segmentation & Impact Analysis
4.1. Non-Small Cell Lung Cancer Market Material Segmentation Analysis
4.2. Industrial Outlook
4.2.1. Market indicators analysis
4.2.2. Market drivers analysis
4.2.2.1. Increase in the prevalence of lung cancer
4.2.2.2. Rising investment into R&D
4.2.2.3. Awareness of the disease and its treatment.
4.2.3. Market restraints analysis
4.2.3.1. High cost of treatment
4.3. Technological Insights
4.4. Regulatory Framework
4.5. ETOP Analysis
4.6. Porter's Five Forces Analysis
4.7. Competitive Metric Space Analysis
4.8. Price trend Analysis

Chapter 5. Non-Small Cell Lung Cancer Market By Histology Insights & Trends
5.1. Histology Dynamics & Market Share, 2019 & 2026
5.2. Squamous Cell Carcinoma
5.2.1. Market estimates and forecast, 2016 – 2026 (USD Billion)
5.2.2. Market estimates and forecast, By Region, 2016 – 2026 (USD Billion)
5.3. Large Cell Carcinoma
5.3.1. Market estimates and forecast, 2016 – 2026 (USD Billion)
5.3.2. Market estimates and forecast, By Region, 2016 – 2026 (USD Billion)
5.4. Adenocarcinoma
5.4.1. Market estimates and forecast, 2016 – 2026 (USD Billion)
5.4.2. Market estimates and forecast, By Region, 2016 – 2026 (USD Billion)

Chapter 6. Non-Small Cell Lung Cancer Market By Treatment Insights & Trends

Continued…..

Get the full TOC of the Report @ https://www.reportsanddata.com/report-detail/non-small-cell-lung-cancer-market/toc

Thank you for reading our report. The report can be customized based on regional segmentation and competitive landscape. Kindly get in touch with us to know more, and our team will ensure the report is well suited to meet your requirements.